(Q38246945)

1 September 2017

1 reference

title

Aminoglycoside-induced nephrotoxicity (English)

1 reference

1 September 2017

Kurt A Wargo

1

1 reference

PubMed ID

25199523

1 September 2017

Jonathan D Edwards

series ordinal

2

1 reference

1 September 2017

7 September 2014

1 reference

Journal of Pharmacy Practice

1 September 2017

1 reference

1 September 2017

27

1 reference

1 September 2017

6

1 reference

1 September 2017

573-577

1 reference

Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides

1 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Impact of dosage schedule of antibiotics on the treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Role of pharmacokinetics in the outcome of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Aminoglycoside antibiotics in the 21st century.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Risk factors for toxicity in elderly patients given aminoglycosides once daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Pharmacodynamics and dosing of aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Comparative clinical study of tobramycin and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

What is the evidence for once-daily aminoglycoside therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Single or multiple daily doses of aminoglycosides: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Once versus thrice daily gentamicin in patients with serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Aminoglycoside dosing considerations in intensive care unit patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546836

21 January 2018

Identifiers

DOI

10.1177/0897190014546836

1 reference

1 September 2017

1 reference

PubMed ID

25199523